Navigation Links
InterMune Announces Launch of Esbriet® (pirfenidone) in Germany
Date:9/12/2011

BRISBANE, Calif., Sept. 12, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Esbriet® (pirfenidone) will be offered to patients in Germany beginning September 15, 2011.  This will mark the first time Esbriet will be commercially available in Europe since it was approved by the European Commission in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF), a devastating and fatal lung disease.  Details on the launch of Esbriet in Germany will be discussed today during a conference call and webcast hosted by InterMune.

"This first launch of Esbriet is an important occasion for patients in Germany and for InterMune," said Dan Welch, Chairman, Chief Executive Officer and President of InterMune. "For the first time, German patients with IPF will have access to a medicine proven to reduce the decline in lung function, offering a treatment where none existed previously.  Our team in Germany is well staffed and trained, and fully committed to making Esbriet available to all appropriate patients as rapidly as possible and our entire organization is actively preparing to launch Esbriet throughout Europe beginning in the first half of 2012."

Conference Call and Webcast Details

InterMune will host a conference call and webcast to provide details on the launch of Esbriet in Germany, including, but not limited to information on the size and structure of the German team, the targeting of the sales force, the commercial and medical education strategy for Esbriet and the pricing of Esbriet in Germany.  The company will also provide an update on other aspects of its business beyond the German launch.

Investors, analysts and other interested parties may participate in the conference call at 8:30 a.m. EDT today by dialing 888-567-5125 (U.S.) or 706-643-9223 (international), conference I
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
2. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
3. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
4. InterMune to Present at J.P. Morgan Healthcare Conference
5. InterMune Reports Third Quarter 2010 Financial Results
6. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
7. InterMune to Release Second Quarter Financial Results on July 27
8. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
9. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
10. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
11. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Executive Officer of Neurocrine Biosciences, will be presenting at the ... in Boston.   The live presentation takes place ... 8:20 a.m. Pacific Time.  The presentation will be webcast and ... . If you are unable to attend ...
(Date:5/23/2013)... Hearing health affects a man,s lifestyle, and if ... and professionally engaged, he should address any hearing loss he ... Better Hearing Institute (BHI) is delivering to men ... Week , which leads up to and includes Father,s Day. ... through June 16. To help men address ...
(Date:5/23/2013)... 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: ... based on intellectual property developed and owned by ... foremost medical research center, today announced that its ... funding from the Israeli Ministry of Industry and ... support product development and advance clinical trials. Cell ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... Mich., Aug. 6 Terumo Heart, Inc. announced,that ... Ventricular Assist,System (LVAS) took place on July 30 ... Arbor, Michigan. The surgery was performed by,Francis Pagani, ... Pivotal Trial. DuraHeart is the world,s first third,generation ...
... Nexgen Spine, a leading,developer of innovative spinal implants ... today that it has received CE mark,approval to ... European,Union., "We are delighted that the Physio-L(R) ... Alastair Clemow, Ph.D., President and CEO,of Nexgen Spine. ...
Cached Medicine Technology:First DuraHeart(TM) Left Ventricular Assist System Implanted in the U.S. Pivotal Trial 2Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc 2
(Date:5/23/2013)... Onlinefitnessreview.com recently published a comprehensive review of ... makes this diet work and how it compares to ... components of the program: eliminating foods that may slow ... personal motivation that is needed to succeed; and, learning ... the metabolism rate in top gear. , Nutritionist ...
(Date:5/23/2013)... May 23 (HealthDay News) -- People who eat at ... realize -- and teens are the worst offenders, a ... calories in their meals by as much as 34 ... 23 percent, and adults by as much as 20 ... a news release from the Robert Wood Johnson Foundation, ...
(Date:5/23/2013)... May 23, 2013 Susquehanna Health ... offering a comprehensive babysitting training course for adolescents age ... developed by Indianapolis pediatrician Dr. Patricia Keener after a ... of an adult sitter who didn’t know how to ... development program with a medical basis that aims to ...
(Date:5/23/2013)... "triple negative" carries a poor prognosis, with limited treatment ... cancer cells the way it,s supposed to. New research ... respond to chemotherapy, and identifies a mechanism to rectify ... Li, PhD, and his team at Western,s Schulich School ... Numb functions to promote the death of cancer cells ...
(Date:5/23/2013)... DC (PRWEB) May 23, 2013 The ... a great deal of control over their level of ... weight, yet far fewer are actually taking that control. ... Food Information Council (IFIC) Foundation’s 2013 Food & Health ... respondents say it’s possible to have “a great deal ...
Breaking Medicine News(10 mins):Health News:Onlinefitnessreview.com Publishes 7 Day Belly Blast Diet Review 2Health News:How Many Calories in Your Fast-Food Meal? Guess Again 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4
... beauticians may be affected by phthalates in these products, ... Mothers exposed to a common hairspray chemical while at ... with an abnormally placed urinary opening, a new report ... and nail and hair products contain chemicals called phthalates, ...
... BELLEVUE, Wash., Nov. 26 Edifecs, Inc., ... announced today that CNSI has,selected the Edifecs ... implementation of a new Medicaid Management Information ... Social Services (DSS). The Edifecs Healthcare,Accelerator ...
... research team led by Mitchell Lazar, MD, PhD, ... Metabolism at the University of Pennsylvania School of ... coordinates body rhythms and metabolism. , Lazar ... Penn Veterinary Medicine doctoral student Theresa Alenghat, studied ...
... Micromet, Inc. (Nasdaq: MITI ), a ... of cancer, inflammation and autoimmune diseases, today announced that ... will present at the Piper Jaffray 20th Annual Health ... Wednesday, December 3, 2008. A simultaneous webcast of ...
... help regulate appetite , , WEDNESDAY, Nov. 26 (HealthDay News) -- ... this year, a molecule produced in the small intestine will ... brain the impact of the fat you,ve just consumed. , ... a while. But, researchers are hoping that one day variations ...
... across the world are to share skills and experiences ... Africa, organised by the Wellcome Trust. , The conference ... will take place from 2-5 December at the Africa ... bring together practitioners working in the fields of public ...
Cached Medicine News:Health News:CNSI Selects Edifecs Healthcare Accelerator Suite(TM) for MMIS Solution to Support South Dakota Medicaid Program 2Health News:Molecular partnership controls daily rhythms, body metabolism 2Health News:Micromet to Present at the Piper Jaffray 20th Annual Health Care Conference 2Health News:Micromet to Present at the Piper Jaffray 20th Annual Health Care Conference 3Health News:Micromet to Present at the Piper Jaffray 20th Annual Health Care Conference 4Health News:Fat-Sensing Hormones Might Fight Obesity 2Health News:International workshop aims to boost public engagement work in developing countries 2Health News:International workshop aims to boost public engagement work in developing countries 3
... active hormone synthesized within the follicular cells ... synthesized via a series of steps involving: ... (ii) iodination of tyrosine residues in the ... and 3,5-diiodotyrosine (MIT and DIT), and (iii) ...
... factor binding protein-3 (IGFBP-3) is the main binding ... as a component of the ~150 kDa ternary ... of IGF-I or IGF-II and ALS, allowing IGFBP-3, ... the IGFs. The molar concentration of IGFBP-3 in ...
... a monomeric protein produced and stored in ... is released from the pituitary into the ... regulatory control of hypothalamic somatostatin (SS) and ... frequency of GH release appears to be ...
... somatomedin C) is a 7.6 kDa peptide produced ... potent mitogen of cellular proliferation, exerting its actions ... circulation, IGF-I is bound to IGF-binding proteins (IGFBPs), ... by modulating the interaction of IGF-I with the ...
Medicine Products: